Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. (CAPSACOX)

Phase 3 Confirmatory, Randomised 1:1 Double-blind, Placebo-controlled Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

The primary objective is to demonstrate the analgesic effect at day 60 of 8% capsaicin patch (Qutenza) for the treatment of patients with coccygodyinia.

Study Overview

• Status: Recruiting
• Conditions: Neuropathic Pain; Coccyx Disorder; Coccygodynia
• Intervention / Treatment: Drug: Capsaicin 179 Mg Cutaneous Patch; Drug: Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)

Detailed Description

This trial is a French, multicenter, randomized, controlled, bouble-blind and prospective study. Patients enrolled will be clinically followed for 5 months. The treatment duration per subject is 1 hour (1time).

• Study Type: Interventional
• Enrollment (Estimated): 188
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Amélie LEVESQUE, MD; Phone Number: +33240083912; Email: amelie.levesque@chu-nantes.fr

Study Locations

• France
  • Brest, France
    • Recruiting
    • Brest University Hospital
    • Contact: Bertrand QUINIO, MD
    • Principal Investigator: Bertrand QUINIO, MD
  • La Roche-sur-Yon, France
    • Recruiting
    • Vendée Departmental Hospital
    • Contact: Yves-Marie PLUCHON, MD
    • Principal Investigator: Yves-Marie PLUCHON, MD
  • Nantes, France
    • Recruiting
    • Nantes University Hospital
    • Contact: Amélie LEVESQUE, MD
    • Principal Investigator: Amélie LEVESQUE, MD
  • Nantes, France
    • Recruiting
    • Confluent Private Hospital Centre
    • Contact: Thibault RIANT, MD
    • Principal Investigator: Thibault RIANT, MD
  • Paris, France
    • Recruiting
    • GH Paris saint Joseph
    • Contact: Marguerite D'USSEL, MD
    • Principal Investigator: Marguerite D'USSEL, MD
  • Rouen, France
    • Recruiting
    • Rouen University Hospital
    • Contact: Rodrigue DELEENS, MD
    • Principal Investigator: Rodrigue DELEENS, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• >18 years old at the pre-inclusion visit
• Presenting with chronic coccygodynia: pain in the coccygeal region, increased by sitting and or when rising from a sitting position and pain over the last ten days of intensity greater than or equal to four on the eleven-point numerical scale (from zero to ten) and having been present for more than 3 months.
• Failure of previous treatments: NSAIDs, pressure-relieving cushions, infiltration (for hypermobile coccygodynia)
• Have never been treated with an 8% capsaicin patch for this indication
• With at least one clinical sign suggestive of neuropathic pain (burning, painful cold, numbness, tingling, electric discharge, allodynia of the gluteal groove, allodynia to pressure on the coccyx)
• Proficiency in reading and writing the French language
• Be affiliated to the social security system
• Have signed an informed consent form
• Women must meet one of the following criteria at the time of inclusion:
• be using adequate contraceptive measures, and have a negative pregnancy test (specify if urine or blood test) prior to receiving the first dose of trial medication;
• or be post-menopausal (aged over 50 with amenorrhoea for at least 12 months after stopping all exogenous hormonal treatments)
• or (if under 50) have been in amenorrhoea for at least 12 months after stopping all exogenous hormone treatments and with luteinising hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels.
• or have undergone irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).

Exclusion Criteria:

• Coccygodynia accompanied by a dermatological lesion in the intergluteal cleft (psoriasis, pilodinial cyste, wound)
• Patients with other major pain disorders likely to interfere with pain assessment
• Hypersensitivity to capsaicin or to one of the excipients
• Adults under legal protection (guardianship, curatorship, legal protection)
• Pregnant or breast-feeding women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Capsaicin 179 mg cutaneous patch; Capsaicin 179 mg cutaneous patch. 1 patch applied once for 1 hour at inclusion visit.	Drug: Capsaicin 179 Mg Cutaneous Patch; 1 patch applied once for 1 hour; Other Names: qutenza
Placebo Comparator: Capsaicin low concentration patch; Capsaicin 0.04 cutaneous patch. 1 patch applied once for 1 hour at inclusion visit	Drug: Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2); 1 patch applied once for 1 hour

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
to demonstrate the analgesic effect at day 60 of 8% capsaicin patch (Qutenza) for the treatment of patients with coccygodyinia.	The difference in the proportion of subjects improved (PGIC≤2) in either treatment group at day 60. It is expected that there will be a difference of at least 20% between treatment arms.	Day 60

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the tolerability of the 8% capsaicin patch compared to low concentration capsaicin patch (control) within the first 7 days	Tolerability will be assessed by the evolution over time of the pain intensity in standing position in the treated zone as measured on an 11 point numeric rating scale at time 0 (prior to patch application), hour 1, 6, 12, 24, day 2 and day 7 and by collecting AEs during the study.	time 0 (prior to patch application), hour 1, 6, 12, 24, day 2 and day 7 and by collecting AEs during the study.time 0 (prior to patch application), hour 1, 6, 12, 24, day 2 and day 7 and through study completion (an average of 5 months)
Evaluate the safety of the capsaicin 8% patch compared with the control patch throughout the study.	Safety will be assessed by recording and describing adverse events throughout the study.	Throughout the study (an average of 5 months)
Evaluation of the analgesic effect over time and maintenance of effect in the two treatment groups over the entire study.	The timecourse of the analgesic effect will be measured by the Patients' Global Impression of Change (PGIC) scale and the area under the pain intensity score in sitting position as measured Day 2, Day 7, Day 15, Day 21, Day 30, Day 45, Day 60, Day 90, Day 120 and Day 150.	Day 2, Day 7, Day 15, Day 21, Day 30, Day 45, Day 60, Day 90, Day 120 and Day 150.
Evaluation of health care consumption in the two treatment groups over the entire study period (5 months).	Care consumption will be assessed over 5 months using the Medication Quantification Scale (MQS), which provides a standardised assessment of consumption of analgesics and co-antalgesics.	Over 5 months
Evaluation of health care consumption in the two treatment groups over the entire study period (5 months).	Care consumption will be assessed over 5 months using a self-diary in which patients will enter the dates of medical consultations (psychiatry, rheumatology, general medicine, etc.), para-medical consultations and/or complementary medical consultations (physiotherapy, acupuncture, osteopathy, psychotherapy, etc.).	Over 5 months
Evaluation of the cost-utility of 8% capasaicin patch with common clinical practice over a time horizon of 5 months	The evaluation of cost-utility will be assessed as the ratio of the incremental cost-utility (RICU in cost per QALY gained) comparing the treatment with 8% capsaicin patch with usual practice according to the collective perspective and a 5-month horizon. QALYS will be calculated using patients' lifespan and a utility score obtained from responses to the EQ-5D-5L generic quality of life questionnaire.	Over a time horizon of 5 months
Determination of the therapeutic response to 8% capsaicin patch	Measurement of the association between the patient's intrinsic clinical parameters and a therapeutic response to capsaicin defined by a PGIC ≤2.	Day 60
Sensitivity study to compare results on the primary endpoint by comparing data from the PGI-C and a comparison of the two numerical pain assessments at Day 0 and Day 60.	Comparison of the classification of patients as success-failure between PGI-C values at Day 60 (success if PGI-C≤2) and numerical pain assessments between Day 0 and Day 60 (success if there is a reduction of at least 2 points on the EN).	Between Day 0 and Day 60
Analysis of primary and secondary endpoints according to the presence or absence of sacrococcygeal hypermobility.	Subgroup analysis according to the presence or absence of a sacrococcygeal mobility disorder at inclusion for the primary endpoint and the first two secondary endpoints.	At inclusion

Collaborators and Investigators

• Sponsor: Nantes University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2023
• Primary Completion (Estimated): January 8, 2027
• Study Completion (Estimated): June 8, 2027

Study Registration Dates

• First Submitted: August 1, 2023
• First Submitted That Met QC Criteria: September 4, 2023
• First Posted (Actual): September 5, 2023

Study Record Updates

• Last Update Posted (Estimated): April 26, 2024
• Last Update Submitted That Met QC Criteria: April 25, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Neuromuscular Diseases; Peripheral Nervous System Diseases; Neuralgia; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Dermatologic Agents; Antipruritics; Capsaicin
• Other Study ID Numbers: RC22_0415

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No